Aspen to pay $9.7M to settle U.K. competition concerns


Aspen Pharmacare has offered to pay the U.K.’s National Health Service £8 million (U.S. $9.7 million) following suspicions that the company paid rival firms to delay marketing a vital medicine to retain market dominance.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.